Rare hyperlipidemia

Rare hyperlipidemia (Orphanet code 181422) is a broad grouping category within the Orphanet classification that encompasses uncommon disorders of lipid metabolism characterized by abnormally elevated levels of lipids (fats) in the blood. These conditions primarily affect the cardiovascular system, as chronic elevation of blood lipids—including cholesterol and triglycerides—leads to accelerated atherosclerosis, which can result in premature coronary artery disease, stroke, and peripheral vascular disease. Depending on the specific subtype, other organ systems may also be involved, including the skin (xanthomas, xanthelasma), the liver, the spleen (hepatosplenomegaly in severe hypertriglyceridemia), and the pancreas (recurrent pancreatitis in cases of extreme triglyceride elevation). This category includes a number of distinct genetic conditions such as familial hypercholesterolemia, familial combined hyperlipidemia, familial dysbetalipoproteinemia (type III hyperlipoproteinemia), familial hypertriglyceridemia, and other rare monogenic or oligogenic lipid disorders. Each subtype has its own specific genetic basis, inheritance pattern, and clinical presentation. Key symptoms across these conditions may include tendon xanthomas, corneal arcus at a young age, eruptive xanthomas, lipemia retinalis, and early-onset cardiovascular events. Treatment approaches vary by subtype but generally include lifestyle modifications (dietary changes, exercise, weight management) and pharmacological therapies such as statins, ezetimibe, PCSK9 inhibitors, fibrates, and omega-3 fatty acids. For the most severe forms, such as homozygous familial hypercholesterolemia, advanced therapies including LDL apheresis, lomitapide, mipomersen, and liver transplantation may be considered. Early diagnosis and aggressive management are critical to reducing cardiovascular morbidity and mortality.

Common questions about Rare hyperlipidemia